首页> 外文期刊>Metallomics >99mTc-labeling of ciprofloxacin and nitrofuryl thiosemicarbazone using fac-[99mTc(CO)3(H2O)3] core: evaluation of their efficacy as infection imaging agents
【24h】

99mTc-labeling of ciprofloxacin and nitrofuryl thiosemicarbazone using fac-[99mTc(CO)3(H2O)3] core: evaluation of their efficacy as infection imaging agents

机译:使用fac-[ 99m Tc(CO) 3 (H 2 ) 99m 环丙沙星和硝基呋喃硫代氨基脲的Tc标记O) 3 ]核心:评价其作为感染显像剂的功效

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to radiolabel ciprofloxacin (Cip) and nitrofuryl thiosemicarbazone (NFT) with the fac-[99mTc(CO)3(H2O)3]+ core and to evaluate the ability of the radiopharmaceuticals as tracers in detecting sites of infection. Cip and NFT were radiolabeled with the fac-[99mTc(CO)3(H2O)3]+ core and characterized by RHPLC. The stabilities of the preparations were evaluated in saline and rat serum. In vitro binding studies of the radiopharmaceuticals with S. aureus were performed. Biodistribution studies were conducted at different time points after injecting (i.v.) the radiopharmaceuticals in rats (intramuscularly infected with S. aureus) as well as in rats with sterile inflammation. To assess the infection targeting capacity of 99mTc-tricarbonyl ciprofloxacin and nitrofuryl thiosemicarbazone, 99mTc(V)O-Cip and 99mTc(V)O-NFT were used as control. Scintigraphic imaging studies of tricarbonyl compounds and 99mTc(V)O-Cip were performed at 4 h after injection. The radiochemical purities of 99mTc(CO)3-Cip and 99mTc(CO)3-NFT were between 97–98% as determined by thin layer chromatography (TLRC) and RHPLC; no further purification is necessary before injection. The radiopharmaceuticals exhibited substantial stability when incubated in isotonic saline and serum up to 24 h. Biodistribution studies showed maximum uptake in the infected rat thigh muscle at 4 h post injection and washing out at slower rate from the infected site than the oxo technetium chelate. The mean ratios of uptake in infectedon–infected thighs were 3.87:1, 3.41:1 and 3.17:1 for 99mTc(CO)3-Cip, 99mTc(CO)3-NFT and 99mTc(V)O-Cip respectively. During scintigraphic studies, infection sites appeared quite distinctly with 99mTc(CO)3-Cip and 99mTc(CO)3-NFT, comparable to the behaviour with 99mTc(V)O-Cip. These results encouraged us for further development of infection imaging radiopharmaceuticals based on the 99mTc-tricarbonyl core.
机译:这项研究的目的是用fac-[ 99m Tc(CO) 3 (H 2 <标记)放射性标记环丙沙星(Cip)和硝基呋喃硫代半乳糖苷(NFT)。 / sub> O) 3 ] + 核心,并评估放射性药物作为示踪剂检测感染部位的能力。用fac-[ 99m Tc(CO) 3 (H 2 O) 3 放射性标记Cip和NFT ] + 核心,并通过RHPLC表征。在盐水和大鼠血清中评估制剂的稳定性。进行了放射性药物与金黄色葡萄球菌的体外结合研究。在大鼠(肌肉内感染金黄色葡萄球菌)和无菌炎症大鼠中注射(静脉内)放射性药物后,在不同时间点进行生物分布研究。为了评估 99m Tc-三羰基环丙沙星和硝基呋喃硫半乳糖, 99m Tc(V)O-Cip和 99m Tc(V O-NFT用作对照。注射后4 h对三羰基化合物和 99m Tc(V)O-Cip进行闪烁显像。 99m Tc(CO) 3 -Cip和 99m Tc(CO) 3 -NFT的放射化学纯度分别为通过薄层色谱法(TLRC)和RHPLC测定,介于97-98%之间;注射前无需进一步纯化。当在等渗盐水和血清中孵育长达24小时时,放射性药物显示出基本的稳定性。生物分布研究表明,注射后4 h,受感染的大鼠大腿肌肉的摄取量最大,并且从被感染部位冲洗的速度比含氧tech螯合物要慢。 99m Tc(CO) 3 -Cip,的受感染/未受感染大腿的平均摄取率分别为3.87:1、3.41:1和3.17:1 > 99m Tc(CO) 3 -NFT和 99m Tc(V)O-Cip。在闪烁显像研究中,感染部位以 99m Tc(CO) 3 -Cip和 99m Tc(CO) 3 < / sub> -NFT,相当于 99m Tc(V)O-Cip的行为。这些结果鼓励我们进一步开发基于 99m Tc-三羰基核的感染成像放射性药物。

著录项

  • 来源
    《Metallomics》 |2011年第10期|p.1041-1048|共8页
  • 作者单位

    1. Nuclear Medicine Division,Indian Institute of Chemical Biology (CSIR), 4, Raja S. C. Mullick Road, Jadavpur, Kolkata-700032, India;

    1. Nuclear Medicine Division,Indian Institute of Chemical Biology (CSIR), 4, Raja S. C. Mullick Road, Jadavpur, Kolkata-700032, India;

    1. Nuclear Medicine Division,Indian Institute of Chemical Biology (CSIR), 4, Raja S. C. Mullick Road, Jadavpur, Kolkata-700032, India;

    1. Regional Radiation Medicine Centre,Thakurpukur Cancer Centre and Welfare Home Campus, Kolkata, India;

    1. Regional Radiation Medicine Centre,Thakurpukur Cancer Centre and Welfare Home Campus, Kolkata, India;

    1. Regional Radiation Medicine Centre,Thakurpukur Cancer Centre and Welfare Home Campus, Kolkata, India;

    1. Nuclear Medicine Division,Indian Institute of Chemical Biology (CSIR), 4, Raja S. C. Mullick Road, Jadavpur, Kolkata-700032, India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号